• Other
  • Exited

Pharmasset, Inc. (NASDAQ: VRUS) is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset’s research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.  Pharmasset was acquired by Gilead Sciences in January 2012 for $11.2 billion.